dimarts, 1 de juliol del 2014

Study: Early CoreValve patients saw growing leakage, mortality risk




Valve leakage and cardiovascular mortality increased significantly over the course of a 3-year study of early high-risk patients treated with Medtronic's CoreValve TAVI system, but researchers insist the results are still "amazingly good."





Study: Early CoreValve patients plagued by side effects at 3 years

Medtronic

News Well, Clinical Trials, Implants, Replacement Heart Valves

read more






from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1rdeqvP
Publicat per a
Etiquetes de comentaris: ,

Cap comentari:

Publica un comentari a l'entrada

Subscriure's a: Comentaris del missatge (Atom)